In the literature: August 2018 by Juan-Miguel Cejalvo, Gema Bruixola, Federica Papaccio

Get full text

In the literature: June 2020 by Juan-Miguel Cejalvo, Valentina Gambardella, Andrés Cervantes, Desamparados Roda

Get full text

In the literature: April 2019 by Gema Bruxiola, Juan-Miguel Cejalvo, Valentina Gambardella, Andrés Cervantes

Get full text

In the literature: June 2019 by Juan-Miguel Cejalvo, Valentina Gambardella, Andrés Cervantes, Tania Fleitas-Kanonnikoff, Angela Lamarca

Get full text

miRNA Expression Analysis: Cell Lines HCC1500 and HCC1937 as Models for Breast Cancer in Young Women and the miR-23a as a Poor Prognostic Biomarker by Sara S Oltra, Maria Peña-Chilet, Maria T Martinez, Eduardo Tormo, Juan Miguel Cejalvo, Joan Climent, Pilar Eroles, Ana Lluch, Gloria Ribas

Get full text

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer. by Denis Collins, Wolfgang Jacob, Juan Miguel Cejalvo, Maurizio Ceppi, Ian James, Max Hasmann, John Crown, Andrés Cervantes, Martin Weisser, Birgit Bossenmaier

Get full text

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study by Sonia Pernas, Sonia Pernas, Patricia Villagrasa, Ana Vivancos, Maurizio Scaltriti, Jordi Rodón, Jordi Rodón, Octavio Burgués, Paolo Nuciforo, Jordi Canes, Laia Paré, Marta Dueñas, Marta Dueñas, Maria Vidal, Maria Vidal, Maria Vidal, Juan Miguel Cejalvo, Juan Miguel Cejalvo, Juan Miguel Cejalvo, Antonia Perelló, Antonio Llommbard-Cussac, Joan Dorca, Alvaro Montaño, Tomás Pascual, Mafalda Oliveira, Mafalda Oliveira, Gloria Ribas, Gloria Ribas, Inmaculada Rapado, Aleix Prat, Aleix Prat, Aleix Prat, Aleix Prat, Eva Ciruelos, Eva Ciruelos

Get full text

miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies by Iris Garrido‐Cano, Anna Adam‐Artigues, Ana Lameirinhas, Juan F. Blandez, Vicente Candela‐Noguera, Federico Rojo, Sandra Zazo, Juan Madoz‐Gúrpide, Ana Lluch, Begoña Bermejo, Felix Sancenón, Juan Miguel Cejalvo, Ramón Martínez‐Máñez, Pilar Eroles

Get full text

MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer by Sandra Torres-Ruiz, Iris Garrido-Cano, Ana Lameirinhas, Octavio Burgués, Cristina Hernando, María Teresa Martínez, Federico Rojo, Begoña Bermejo, Marta Tapia, Juan Antonio Carbonell-Asins, Carlos Javier Peña, Ana Lluch, Juan Miguel Cejalvo, Eduardo Tormo, Pilar Eroles

Get full text

A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small... by Enriqueta Felip, Juan-Miguel Cejalvo, Wolfgang Jacob, Tania Fleitas Kanonnikoff, Alejandro Navarro Mendivil, Maria Martinez Garcia, Alvaro Taus Garcia, Natasha Leighl, Ulrik Lassen, Morten Mau-Soerensen, Celine Adessi, Francesca Michielin, Ian James, Maurizio Ceppi, Max Hasmann, Martin Weisser

Get full text

NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer by Sara Santana-Hernández, Jesús Suarez-Olmos, Sonia Servitja, Pau Berenguer-Molins, Marcel Costa-Garcia, Laura Comerma, Anna Rea, Julia Perera-Bel, Silvia Menendez, Oriol Arpí, Begoña Bermejo, María Teresa Martínez, Juan Miguel Cejalvo, Iñaki Comino-Méndez, Javier Pascual, Emilio Alba, Miguel López-Botet, Federico Rojo, Ana Rovira, Joan Albanell, Aura Muntasell

Get full text

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer by Francesco Schettini, Nuria Chic, Fara Brasó-Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez-Sáez, Barbara Adamo, Maria Vidal, Esther Barnadas, Aranzazu Fernández-Martinez, Blanca González-Farre, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos H. Barrios, Ana Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat

Get full text

Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer by Francesco Schettini, Nuria Chic, Fara Brasó-Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez-Sáez, Barbara Adamo, Maria Vidal, Esther Barnadas, Aranzazu Fernández-Martinez, Blanca González-Farre, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos H. Barrios, Ana Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat

Get full text

HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with... by Rubén Olivera-Salguero, Elia Seguí, Elia Seguí, Elia Seguí, Juan Miguel Cejalvo, Juan Miguel Cejalvo, Mafalda Oliveira, Mafalda Oliveira, Mafalda Oliveira, Pablo Tolosa, Pablo Tolosa, Maria Vidal, Maria Vidal, Maria Vidal, Maria Vidal, Marcos Malumbres, Marcos Malumbres, Marcos Malumbres, Joaquín Gavilá, Joaquín Gavilá, Cristina Saura, Cristina Saura, Sonia Pernas, Sonia Pernas, Rafael López, Rafael López, Mireia Margelí, Mireia Margelí, Judith Balmaña, Judith Balmaña, Montserrat Muñoz, Montserrat Muñoz, Montserrat Muñoz, Isabel Blancas, Isabel Blancas, Valentina Boni, Valentina Boni, Eva Ciruelos, Eva Ciruelos, Eva Ciruelos, Elena Galve, Elena Galve, Antonia Perelló, Antonia Perelló, Rodrigo Sánchez-Bayona, Rodrigo Sánchez-Bayona, Susana de la Cruz, Susana de la Cruz, Miguel de la Hoya, Patricia Galván, Esther Sanfeliu, Esther Sanfeliu, Esther Sanfeliu, Blanca Gonzalez-Farre, Blanca Gonzalez-Farre, Blanca Gonzalez-Farre, Valeria Sirenko, Aura Blanch-Torras, Jordi Canes, Helena Masanas, Rosa Olmos, Margarita Forns, Aleix Prat, Aleix Prat, Aleix Prat, Aleix Prat, Ana Casas, Ana Casas, Tomás Pascual, Tomás Pascual

Get full text

Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response by Fara Brasó-Maristany, Juan Manuel Ferrero-Cafiero, Claudette Falato, Olga Martínez-Sáez, Juan Miguel Cejalvo, Mireia Margelí, Pablo Tolosa, Francisco Javier Salvador-Bofill, Josefina Cruz, Blanca González-Farré, Esther Sanfeliu, Andreu Òdena, Violeta Serra, Francisco Pardo, Ana María Luna Barrera, Miriam Arumi, Juan Antonio Guerra, Guillermo Villacampa, Rodrigo Sánchez-Bayona, Eva Ciruelos, Martín Espinosa-Bravo, Yann Izarzugaza, Patricia Galván, Judith Matito, Sonia Pernas, Maria Vidal, Anu Santhanagopal, Dalila Sellami, Stephen Esker, Pang-Dian Fan, Fumitaka Suto, Ana Vivancos, Tomás Pascual, Aleix Prat, Mafalda Oliveira

Get full text